Comparison of Respiratory Complications of COVID-19 among Patients with Rheumatological Conditions Taking Biological Disease-Modifying Anti-Rheumatic Drugs and Conventional Synthetic Disease-Modifying Antirheumatic Drugs

Objective: To compare the respiratory complications of COVID-19 among patients with rheumatological conditions taking bDMARDs and csDMARDs at Pak Emirates Military Hospital Rawalpindi.
 Study Design: Comparative prospective study.
 Place Duration Study: Hospital, Rawalpindi Pakistan from Mar to May 2020.
 Methodology: Patients diagnosed on polymerase chain reaction having previously managed either bDMARD or cs DMARD were included in study. They followed up for three weeks after positive reaction. Complications leading use oxygen ICU support death compared both groups patients.
 Results: A total 82 any condition csDMARD tested covid-19 final analysis. 30 (36.6%) while 52 (63.4%) csDMARD. In addition, 4 (4.8%) low dose therapy, 5 (6.1%) required moderate severe therapy intensive care unit support. 2 (2.4%) died within weeks. The requirement was found statistically significantly more group csDMARDS.
 Conclusion: presence COVID -19 present some DMARDs. Among DMARDs, less linked complications, but large studies better design results.